Gilde Healthcare leads £6 million ($9.4 million) financing round of Digital Health company Qinec - Gilde Healthcare

Gilde Healthcare leads £6 million ($9.4 million) financing round of Digital Health company Qinec

9 June 2015

London – Qinec, a pioneer in Personalized Healthcare Management, today announced that it has secured £6 million in Series B funding, led by Gilde Healthcare. Existing investors Amadeus Capital Partners and Archimedia participated as well.

Qinec will use the funding to scale the team and further expand within a Healthcare IT market segment predicted to be worth over $1.3 billion.

Qinec, which counts Alliance Medical and Optegra Eye Health Care amongst its customers, uses real-time data to personalize the patient journey resulting in optimal outcomes for patients, providers and payers whilst simultaneously reducing cost. Its cloud-based Software as a Service (SaaS) platform today supports millions of patient journeys a year across Europe.

As part of the investment, Janke Dittmer, partner at Gilde Healthcare, joins the Board as a Non-Executive Director and Erik Masing as an Advisor. Additionally, Qinec is strengthening its executive team with the introduction of Andrew Wyatt as Chief Operating Officer. Andrew brings a depth of experience in successfully scaling software and SaaS businesses, including BroadSoft Inc (NASDAQ: BSFT) where he was VP Strategy and Apertio Ltd where he was Chief Product Operations Officer and interim CEO.

About Qinec
Qinec is a UK-based digital health company providing Personalized Healthcare Management (PHM) solutions. The company’s cloud-based SaaS platform uses real time data to orchestrate the patient journey to achieve optimal outcomes for patients, providers and payers at lower cost.
Managing millions of patients a year across Europe, Qinec tailors processes and optimizes clinical and administrative workflows across every specialty of outpatient care. For more information about Qinec please visit www.qinec.com.

About Gilde Healthcare
Gilde Healthcare (Utrecht, The Netherlands and Cambridge, Massachusetts, US) is a private equity investor focused on fast growing healthcare businesses. It manages €550 million across two business lines. The Gilde Healthcare Technology funds target companies developing home & digital health solutions, medical devices and therapeutics in Europe and the US. The Gilde Healthcare Services funds focus on healthcare service providers, such as specialist clinics, elderly care, primary care and other service providers in the Benelux and Germany.
For a list of Gilde’s portfolio companies please visit the website at www.gildehealthcare.com.

Gilde Healthcare portfolio company Nyxoah announces CE-mark approval to treat complete concentric collapse (CCC) patients

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that DEKRA Notified Body has approved...
5 October 2021

Gilde Healthcare portfolio company Noema Pharma appoints Jeffrey Jonas as Independent Chairman of the Board of Directors

Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the appointment of Jeffrey Jonas MD as Chairman of the Board of Directors. Dr. Jonas is a neuropsychiatry expert...
4 October 2021

Gilde Healthcare company Acacia Pharma announces marketing authorization application for BARHEMSYS® in Europe

Acacia Pharma (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or cancer chemotherapy, announces...
29 September 2021